Results 31 to 40 of about 9,681 (277)

Facteurs de risque cardiovasculaires au cours du lupus systémique

The Pan African Medical Journal, 2015
Cette étude a pour objectif d'évaluer la fréquence des facteurs de risque cardiovasculaires au cours du lupus et de préciser leur prévalence. Etude rétrospective portant sur 250 patients ayant un lupus, diagnostiqué selon les critères de l'ACR ...
Amel Harzallah, Mariem Hajji, Hayet Kaaroud, Fethi Ben Hamida, Taieb Ben Abdallah   +4 more
doaj   +1 more source

Familial Hypercholesterolemia and the Founder Effect Among Franco-Americans: A Brief History and Call to Action

CJC Open, 2020
Familial hypercholesterolemia (FH) is an inherited disorder characterized by chronically elevated low-density lipoprotein cholesterol levels and an increased risk of premature atherosclerotic cardiovascular disease.
Reed Mszar, BS, Sara Buscher, BS, Heidi L. Taylor, PhD, Mary T. Rice-DeFosse, PhD, Dervilla McCann, MD, MPH, FACC   +4 more
doaj   +1 more source

Challenges in Initiating Antiretroviral Therapy in 2010

Canadian Journal of Infectious Diseases and Medical Microbiology, Volume 21, Issue C, Page 1C-15C, 2010., 2010
Many clinical trials have shown that initiating antiretroviral therapy (ART) at higher rather than lower CD4 T cell‐positive counts results in survival benefit. Early treatment can help prevent end‐organ damage associated with HIV replication and can decrease infectivity.
Cécile L Tremblay, Jean-Guy Baril, David Fletcher, Donald Kilby, Paul MacPherson, Stephen D Shafran, Mark W Tyndall   +6 more
wiley   +1 more source

Morbidité et mortalité hospitalière des maladies cardiovasculaires en milieu tropical: exemple d'un centre hospitalier à Lomé (Togo)

The Pan African Medical Journal, 2014
INTRODUCTION: Les maladies cardiovasculaires (MCV) occupent une place importante dans la mortalité en Afrique, situation inquiétante traduisant une transition épidémiologique rapide.
Findibe Damorou, Soodougoua Baragou, Machihuede Pio, aovi M Afassinou, Nékenon W Néda, Soulemane Pessinaba, Tchaa Tchérou, Halé Attiogbé, Koffi Ehlan, Edem Goeh-Akue, Komlavi Yayehd   +10 more
doaj   +1 more source

Increasing Prevalence and Incidence of Atherosclerotic Cardiovascular Disease in Adult Patients in Ontario, Canada From 2002 to 2018

CJC Open, 2022
Background: Cardiovascular disease is the second-leading cause of death in Canada. However, limited data are available on the prevalence of atherosclerotic cardiovascular disease (ASCVD) in Canada.
Erin S. Mackinnon, PhD, Ron Goeree, BA, MA, Shaun G. Goodman, MD, MSc, Raina M. Rogoza, MSc, Millicent Packalen, BSc(Hons), Louisa Pericleous, PhD, Ponda Motsepe-Ditshego, MD, Paul Oh, MD, MSc, FRCPC   +7 more
doaj   +1 more source

Analysis of Hospital Discharge Data to Characterize Obstructive Sleep Apnea and Its Management in Adult Patients Hospitalized in Canada: 2006 to 2007

Canadian Respiratory Journal, Volume 17, Issue 5, Page 213-218, 2010., 2010
BACKGROUND: Diagnosed obstructive sleep apnea (OSA) affects 2% to 7% of middle‐age persons worldwide and represents a substantial health care burden. The gold standard for treating OSA in adults is continuous positive airway pressure (CPAP) therapy. Compliance with this treatment is especially important in OSA patients experiencing concomitant acute ...
Kathy F Spurr, Debra L Morrison, Michael A Graven, Adam Webber, Robert W Gilbert   +4 more
wiley   +1 more source

Association of Acute Anti-inflammatory Treatment With Medium-term Outcomes for Coronary Artery Aneurysms in Kawasaki Disease

CJC Pediatric and Congenital Heart Disease, 2022
Background: The impact of adjunctive anti-inflammatory treatment on outcomes for patients with Kawasaki disease (KD) and coronary artery aneurysms (CAAs) is unknown.
Kevin G. Friedman, MD, Brian W. McCrindle, MD, MPH, Kyle Runeckles, MSc, Nagib Dahdah, MD, Ashraf S. Harahsheh, MD, Michael Khoury, MD, Sean Lang, MD, Cedric Manlhiot, PhD, Adriana H. Tremoulet, MD, MAS, Geetha Raghuveer, MD, Elif Seda Selamet Tierney, MD, Pei-Ni Jone, MD, Jennifer S. Li, MD, MHS, Jacqueline R. Szmuszkovicz, MD, Kambiz Norozi, MD, PhD, Supriya S. Jain, MD, Angela T. Yetman, MD, Jane W. Newburger, MD, MPH, Carolyn A. Altman, MD, Brett R. Anderson, MD, MBA, MS, Mikayla Beckley, BS, Elizabeth Braunlin, MD, PhD, Jane C. Burns, MD, Michael R. Carr, MD, Nadine F. Choueiter, MD, Jessica H. Colyer, MD, MBA, Frederic Dallaire, MD, PhD, Sarah D. De Ferranti, MD, MPH, Laurent Desjardins, MD, Matthew D. Elias, MD, Anne Ferris, MBBS, Michael Gewitz, MD, Therese M. Giglia, MD, Steven C. Greenway, MD, Kevin C. Harris, MD, MHSc, Kevin D. Hill, MD, MSc, Michelle Hite, Thomas R. Kimball, MD, Shelby Kutty, MD, Lillian Lai, MD, MHA, Simon Lee, MD, Ming-Tai Lin, MD, PhD, Tisiana Low, MD, MSc, Andrew S. Mackie, MD, MSc, Wadi Mawad, MD, Mathew, MSc, Kimberly E. McHugh, MD, Tapas Mondal, MD, Kimberly Myers, MD, Michael A. Portman, MD, Claudia Renaud, MD, Rosie Scuccimarri, MD, S. Kristen Sexson Tejitel, MD, PhD, MPH, Karen M. Texter, MD, Deepika Thacker, MD, Sharon Wagner-Lees, RN-BC, BSN, Kenny Wong, MD, Mei-Hwan Wu, MD, PhD, Varsha Zadokar, MBBS   +57 more
doaj   +1 more source

Activité physique, indice de masse corporelle, masse graisseuse par impédance: lequel de ces facteurs est le plus associé au risque cardiovasculaire pour nos patients? [PDF]

, 2015
Contexte: Les maladies cardiovasculaires représentent la première cause de mortalité en Suisse et dans le reste du monde depuis des années. Pourtant, elles sont le plus souvent causées par des facteurs de risque évitables et modifiables comme le ...
SPRENG, L.
core  

Le lien entre l’alimentation et les maladies cardiovasculaires

One Health & Risk Management, 2023
INTRODUCTION Les maladies cardiovasculaires (MCV) sont la première cause de mortalité avec 17,9 millions de morts, suivi des cancers (9 millions) et des maladies respiratoires (3,9 millions) qui résultent d’une association de facteurs génétiques ...
Ana-Maria ZAVTONI, Cristina DUMITRAS
doaj  

Real-World Insights Into Evolocumab Use in Patients With Hyperlipidemia: Canadian Analysis From the ZERBINI Study

CJC Open, 2022
Background: The 2021 Canadian Cardiovascular Society guidelines recommend proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor therapy in patients with atherosclerotic cardiovascular disease whose low-density lipoprotein cholesterol (LDL-C ...
Milan Gupta, MD, G.B. John Mancini, MD, Rajvi J. Wani, PhD, Vineeta Ahooja, MD, Jean Bergeron, MD, MSc, Priya Manjoo, MD, A. Shekhar Pandey, MD, Maureen Reiner, MS, MA, Johnny Beltran, MD, MSc, Thiago Oliveira, MD, Erin S. Mackinnon, PhD   +10 more
doaj   +1 more source